KLOW Blend Protocol
KLOW is a fixed four-peptide research blend — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg in a single 80 mg vial — combining copper-mediated regeneration, tissue repair, cell-migration, and anti-inflammatory pathways studied individually across its four components.
1What's in the vial
KLOW is a fixed blend — the four peptides are lyophilized together in one vial, so you cannot dose them separately. The mass ratio is always 50 : 10 : 10 : 10 (GHK-Cu is 62.5% of the total).
GHK-Cu
50 mg
62.5%
Copper-mediated regeneration, skin remodeling
BPC-157
10 mg
12.5%
Tissue repair, gut & tendon healing
TB-500
Cell migration, soft-tissue repair
KPV
Anti-inflammatory (α-MSH fragment)
Total: 80 mg per vial
2Reconstitute & dose
Because the ratio is fixed, every draw delivers all four peptides proportionally — you dose the blend, not one peptide. The calculator below shows exactly how many mg of each peptide any draw delivers. Anchor your draw to whichever component you're studying (most researchers anchor to GHK-Cu, the 62.5% majority, or to the BPC-157 / TB-500 tissue-repair range).
A few common reconstitution points for the 80 mg vial (BAC water = bacteriostatic water):
1 mL
80 mg/mL
GHK-Cu 2.5 mg · BPC/TB/KPV 500 mcg each
2 mL
40 mg/mL
GHK-Cu 1.25 mg · BPC/TB/KPV 250 mcg each
4 mL
20 mg/mL
GHK-Cu 625 mcg · BPC/TB/KPV 125 mcg each
These are arithmetic examples of what a draw delivers at a given reconstitution — not dose recommendations. Use the calculator to model your own vial and draw.
3Administration & storage
Route. In research practice KLOW is administered subcutaneously with a U-100 insulin syringe. (GHK-Cu on its own is also studied topically, but the blend is reconstituted and injected.)
Storage. Store the lyophilized vial cold and protected from light; once reconstituted with bacteriostatic water, refrigerate (2–8 °C) and use within the BAC water's preservative window. GHK-Cu is copper-blue in solution — a faint blue tint after reconstitution is expected.
4What each peptide is studied for
GHK-Cu 50 mg
Copper-binding tripeptide; the best-characterized component. Studied for skin remodeling, wound signaling, and antioxidant gene expression.
BPC-157 10 mg
Gastric pentadecapeptide studied in preclinical models for tissue, tendon, and gut-barrier repair.
TB-500 10 mg
Thymosin β4 fragment studied for actin regulation, cell migration, and soft-tissue repair.
KPV 10 mg
C-terminal α-MSH tripeptide (Lys-Pro-Val) studied for anti-inflammatory signaling.
5Evidence
No study evaluates the four-peptide blend together; the evidence base is the individual components' preclinical literature:
Pickart 2015 — GHK-Cu review (PMID 26236730)
He 2022 — BPC-157 rat/dog PK (PMID 36568636)
Sikiric 2018 — BPC-157 preclinical review (PMID 29141577)
Crockford 2010 — TB-500 / Tβ4 preclinical review (PMID 20594025)
6Regulatory & safety
Related tools